PepGen reports Q2 2024 net loss $28.3M; PGN-EDO51 shows 2.15% exon skipping in CONNECT1

PepGen Inc.

Net loss $28.3M ($0.87/sh) for Q2 2024 vs $19.5M ($0.82/sh) YoY; cash $161.3M, runway into 2026.
PGN-EDO51 (DMD) 5mg/kg cohort: mean exon skipping 2.15%, dystrophin increase 0.70% (muscle-adjusted) from baseline; well tolerated.
FREEDOM-DM1 Phase 1 results expected Q4 2024; FREEDOM2-DM1 cleared by Health Canada & MHRA, dosing H2 2024.
PGN-EDO53 (DMD) advancing in IND/CTA-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.